• Thomas M. Loarie

    Co-founder, CEO and Director

  • Thomas M. Loarie

    Co-founder, CEO and Director

    Tom brings more than 36 years of experience as a CEO at both public and private companies. He has translated more than 20 concepts into commercially viable products. He has raised more than $200 million for both public and private companies. Tom began his healthcare career at American Hospital Supply Corp. (now Baxter International), where he held a number of positions with increasing responsibility, including President of its Heyer-Schulte unit. He is a member of the Dean’s Council of the Jacobs School of Engineering at the University of California San Diego and an advisory board member for Enterprise Ireland, Healthcare Angels, and University of California at San Francisco’s Rosenman Institute. Tom co-hosts the Salem Radio Networks’ weekly program, “The Mentors.” He holds a B.S.M.E. degree from the University of Notre Dame and pursued graduate-level coursework in business and finance at the Universities of Minnesota and Chicago

  • Stephen M. Becker, MD

    Chief Scientific and Medical Officer

  • Stephen M. Becker, MD

    Chief Scientific and Medical Officer

    Stephen has had an extensive career, spanning 37 years, in academic, non-profit and biotechnology research focused primarily on HIV treatment and cure. He has initiated, led or participated in more than 150 clinical trials. Prior to joining Bryologyx he served at the Bill & Melinda Gates Foundation, as Deputy Director and Senior Advisor. Previously, Stephen served for 20 years on the faculty at the University of California at San Francisco (UCSF) as a clinician and clinical researcher. He holds an AB degree from the University of Pennsylvania and an MD from SUNY Buffalo.

  • Sam Kongsamut, PhD

    Co-founder, VP of R&D and Director

  • Sam Kongsamut, PhD

    Co-founder, VP of R&D and Director

    Sam has had a more than 25-year career as a pharmacologist in both large pharmaceutical and early stage biotech companies. He has served in research, research management and executive roles at companies including Biochron Therapeutics, Neurotrope Bioscience, and Sanofi and its predecessor companies. He holds a BSc in Biology from the University of Ottawa, an MSc in Biology from the University of Illinois at Chicago and a PhD in Neuropharmacology from the University of Chicago.

  • Ephraim Vidal, PhD

    Director of Pharmaceutical Development

  • Ephraim Vidal, PhD

    Director of Pharmaceutical Development

    Ephraim brings to Bryologyx more than 17 years’ experience in pharmaceutical product development, with expertise in API development and manufacturing from pilot through commercial scale, and in working with contract manufacturing organizations. He has served at companies including Celgene, Codexis, and Hospira. He holds a PhD in Chemistry from Stony Brook University.

  • Reza Ilkhani

    Chief Financial Officer

  • Reza Ilkhani

    Chief Financial Officer

    Reza has more than 20 years of broad finance experience in financial/economic consulting, corporate development and financial management. In addition to financial management roles of increasing responsibility, he has led numerous high-profile assignments in valuations, transaction support and sophisticated modeling for strategic planning and financial forecasting. He holds a BA degree from the University of California at Berkley, an MBA from the University of Chicago and pursued post-graduate studies at University of Oxford.


      Key Advisors

    • Jim Balkovec, PhD

      Medicinal Chemistry

    • Jim Balkovec, PhD

      Medicinal Chemistry

      Jim has been a medicinal chemist in industry for more than 28 years, including 10+ years at Merck and eight years at biotechnology firms. He holds a PhD in Organic Chemistry from the University of Wisconsin-Madison.

    • Sarah Bodary, PhD

      Business Development

    • Sarah Bodary, PhD

      Business Development

      Sarah has a strong background in biopharma in business and drug development, and as an investor. She has served at companies, including Genentech, Schering Plough BioPharma, Johnson & Johnson, Cellular Research, and as a venture partner for SV Life Sciences. Sarah has a BSc and PhD in molecular biology (University of Edinburgh and University of Lausanne respectively) and was a postdoctoral fellow at UCSF.

    • Omar Duramad, PhD

      Preclinical Oncology

    • Omar Duramad, PhD

      Preclinical Oncology

      Omar is an immunologist by training and has worked in industry, with 13+ years of experience in novel immunotherapies. His experience includes early preclinical pharmacology and as well as clinical, regulatory and business development activities. He has a PhD in Immunology and Cancer Biology from the University of Texas MD Anderson Cancer Center.

    • Jenny Keppler

      Regulatory

    • Jenny Keppler

      Regulatory

      Jenny is head of regulatory at TD2 a CRO focused on precision oncology.  She has an extensive background (20+ years) in regulatory affairs, including CMC and clinical.  She is supported by consultants with expertise in CMC, preclinical and clinical regulatory affairs.  

  • John H. Abeles MD

    Co-founder, Chairman

  • John H. Abeles MD

    Co-founder, Chairman

    For more than 36 years, John has founded and been a successful investor in more than 50 medical/pharmaceutical companies. Since March 1992, Dr. Abeles has been the Founder, Sole Investor and General Partner of Northlea Partners LLLP, a private venture capital and private capital family office. Dr. Abeles is also the President and founder of MedVest, Inc., which has provided consulting services to health care and high technology companies since 1980. Prior to his career as an investor, he served in senior capacities at several leading healthcare companies, including Sterling Drug, Pfizer and Revlon Healthcare and as a healthcare analyst at Kidder Peabody. Dr. Abeles holds an MD and degree in pharmacology from the University of Birmingham, England. He is a Fellow of the Royal Society of Medicine, London.

  • Paul A. Wender, PhD

    Co-Founder

  • Paul A. Wender, PhD

    Co-Founder

    Paul is the Bergstrom Professor of Chemistry at Stanford University. Research in his laboratory led to the first practical fully synthetic process for bryostatin-1, which is licensed to the company. His laboratory focuses on chemistry, synthesis, biology, medicine, and materials science using new computational tools, new reactions, reagents, strategies and design. He is a member of the US National Academy of Sciences, a foreign member of the Royal Spanish Academy of Sciences, and a fellow of the American Association for the Advancement of Science and the American Academy of Arts and Sciences. He received his B.S. degree from Wilkes University and his Ph.D. in chemistry from Yale University.

  • Thomas M. Loarie

    Co-founder, CEO and Director

  • Thomas M. Loarie

    Co-founder, CEO and Director

    Tom brings more than 36 years of experience as a CEO at both public and private companies. He has translated more than 20 concepts into commercially viable products. He has raised more than $200 million for both public and private companies. Tom began his healthcare career at American Hospital Supply Corp. (now Baxter International), where he held a number of positions with increasing responsibility, including President of its Heyer-Schulte unit. He is a member of the Dean’s Council of the Jacobs School of Engineering at the University of California San Diego and an advisory board member for Enterprise Ireland, Healthcare Angels, and University of California at San Francisco’s Rosenman Institute. Tom co-hosts the Salem Radio Networks’ weekly program, “The Mentors.” He holds a B.S.M.E. degree from the University of Notre Dame and pursued graduate-level coursework in business and finance at the Universities of Minnesota and Chicago

  • Sam Kongsamut, PhD

    Co-founder, VP of R&D and Director

  • Sam Kongsamut, PhD

    Co-founder, VP of R&D and Director

    Sam has a more than 25-year career as a pharmacologist in both large pharmaceutical and early stage biotech companies. He has served in research, research management and executive roles at companies including Biochron Therapeutics, Neurotrope Bioscience, and Sanofi and its predecessor companies. He holds a BSc in Biology from the University of Ottawa, an MSc in Biology from the University of Illinois at Chicago and a PhD in Neuropharmacology from the University of Chicago.

  • Michael (Yanhui) Ma, MD

  • Michael (Yanhui) Ma, MD

    Michael is Founder and Chairman, SinoCare, a hospital management group based in Beijing. He has more than 40 years of healthcare experience in pharmaceutical research, medtech business development, and hospital delivery system management. He also serves on the board of several healthcare-related corporations that he founded or co-founded in the US and China, including Sinomed and Medical Entrepreneurs II. He also organized and co-founded the International Drug Delivery Society in China, and currently serves as Vice-Chairman of the Society.

  • Clint Severson

  • Clint Severson

    Clint is former Chairman and CEO of Abaxis, Inc., a company he led from a start-up to a publicly held company with over $220 million in revenues, to its acquisition in 2018 for $2 billion. He has had a more than 40 year-career in the healthcare industry. In 2007, he was named Forbes Entrepreneur of the Year.

  • Bruce Jenett

    Company Counsel

  • Bruce Jenett

    Company Counsel

    Bruce, who is Senior Counsel at DLA Piper, has for more than 35 years represented business and finance clients in the life sciences industry. He is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both startups and large multinational corporations.